Navigation Links
Data Presented at 2015 ASCO Genitourinary Symposium Compares, Validates and Demonstrates Utility for GenomeDx's Decipher Test
Date:2/24/2015

SAN DIEGO, Feb. 24, 2015 /PRNewswire/ -- GenomeDx Biosciences today announced that data to be presented at the 2015 ASCO Genitourinary Symposium demonstrates that its Decipher® Prostate Cancer Classifier was able to accurately identify patients with a high probability of metastasis-free survival despite being identified as high risk by standard risk assessment tools. Additionally, researchers showed that Decipher was able to identify which men who historically have been classified as high risk could safely delay radiation treatment and avoid adverse side-effects. The Decipher® Prostate Cancer Classifier is a genomic test capable of predicting the probability of developing metastatic prostate cancer following a prostatectomy. Three clinical validation studies for Decipher will be presented on February 26 at the 2015 ASCO Genitourinary Symposium from 11:30 a.m. to 1:00 p.m. ET in Orlando, FL.

In a new, prospective, blinded evaluation of 260 men classified as intermediate and high risk by NCCN guidelines and treated with radical prostatectomy at Johns Hopkins Medical Institute, Decipher demonstrated that it is an accurate and independent predictor of metastatic disease within 10 years of surgery in a cohort of patients who received no radiation therapy. This latest validation study for Decipher provides additional evidence that the test can identify low risk men based on genomics who may be managed conservatively after surgery. The study also evaluated Decipher and 33 other published prognostic signatures and showed Decipher to be the top predictor of postoperative metastasis. These findings were echoed in another cohort of node-negative high risk men treated at the Cleveland Clinic. In a separate study performed in conjunction with Thomas Jefferson University and Mayo Clinic and published this month in the Journal of Clinical Oncology, Decipher was shown to augment decision making for men considering adjuvant radiation therapy after radiation therapy. All three studies will be presented this week during the 2015 ASCO Genitourinary Symposium.

The studies being presented are:

  • Abstract #154: "A genomic classifier to improve prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy" by Eric A. Klein, et al. (Display board G16)
  • Abstract #168: "A genomic classifier to identify men with adverse pathology post radical prostatectomy who benefit from adjuvant radiation therapy" by Robert B. Den, et al. (Display board H4)
  • Abstract #173: "Validation of the Decipher prostate cancer classifier in intermediate to high-risk men treated with radical prostatectomy but without additional therapy upon PSA rise" by Ashley Ross, et al. (Display board H9)

About Decipher®

The Decipher® Prostate Cancer Classifier is a highly validated and commercially available genomic test for men with intermediate and high risk prostate cancer. Decipher predicts cancer aggressiveness by looking for a unique genomic signature comprised of a validated series of biomarkers associated with metastatic disease. Adding truly unique information to the treatment decision-making process, Decipher generates a risk result that is completely independent and distinct from PSA, Gleason score and other clinical risk factors. Clinical studies from leading cancer centers published in over a dozen medical journals demonstrate that Decipher can accurately predict metastatic disease, which men may benefit from radiation therapy following prostate surgery, and can lead to significant cost-savings for healthcare systems. Decipher was developed in partnership with the Mayo Clinic.

Decipher is covered by Medicare and multiple private insurance plans and is available to eligible US patients through their physicians.

Learn more at: www.DecipherTest.com.

About GenomeDx Biosciences

GenomeDx Biosciences is focused on transforming cancer patient care by putting usable genomic information in the hands of patients and their physicians. GenomeDx is developing and commercializing Decipher®, a highly validated genomic test for predicting metastatic disease in men with prostate cancer. In partnership with leading medical centers, the company has assembled the largest genomic catalogue of prostate cancer tumors in the world, representing billions of data points and more than 20 years of prostate cancer research expertise. Using advanced cloud-based bioinformatics, GenomeDx mines the genomic data to develop proprietary tests that address key clinical questions in cancer patient management. GenomeDx has partnered to share genomic data with leading clinician-scientists worldwide to collaboratively enrich the knowledge and understanding of urologic cancers for the goal of improving global cancer patient care. GenomeDx is based in San Diego, California and Vancouver, British Columbia.

Learn more at www.genomedx.com.

Media Contact:
Ian Stone
Canale Communications
619-849-5388
ian@canalecomm.com

 


'/>"/>
SOURCE GenomeDx Biosciences
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Amgen Highlights Data To Be Presented At American Society of Clinical Oncology Annual Meeting
2. Actinium Pharmaceuticals Clinical Results to be Presented at 8th International Symposium on Targeted Alpha Therapy Conference
3. Stretta Procedure for GERD: Successful 10 Year Follow-Up Data Presented at Digestive Disease Week--Sustained Improvement, Long-Term Efficacy
4. Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania
5. New Clinical Data Presented at EuroPCR Demonstrates that TriGuard Reduces Brain Lesion Volume during TAVR
6. Preclinical and Phase 1 Data of VTX-2337 Presented at 2013 ASCO Annual Meeting Shows Early Activity in Ovarian Cancer
7. ARUP Laboratories Wins Legacy Award Presented by Premier Healthcare Alliance
8. CTI Announces New Data Presented at EHA 2013 Congress Demonstrating the Safety and Tolerability Profile of Pacritinib in Patients with Myelofibrosis
9. Safinamide Phase III Study Results Presented at 2013 MDS Meeting
10. Ibrutinib Monotherapy Clinical Trial Data in Patients with Waldenstroms Macroglobulinemia Presented at the International Conference on Malignant Lymphoma in Lugano, Switzerland
11. New data about the safety and efficacy of linagliptin in adults with type 2 diabetes who have moderate to severe renal impairment presented at ADA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2021)... ... March 29, 2021 , ... The University of Texas Health Science Center ... San Antonio Multispecialty and Research Hospital, a destination center for research and treatment of ... In a nod to the COVID-19 pandemic, the ceremony was held virtually. , William ...
(Date:3/30/2021)... ... March 29, 2021 , ... Iora Health ... primary care, has partnered with Devoted Health , one of the fastest-growing ... across Maricopa County and provides seniors with the highest-quality care and experience possible, ...
(Date:3/30/2021)... CITY (PRWEB) , ... March 29, 2021 , ... ... has joined the Vaccine Credential Initiative (VCI), a group bringing together leading health ... record of vaccination status, based on open, interoperable standards. By joining the VCI ...
Breaking Medicine Technology:
(Date:3/30/2021)... , ... March 29, 2021 , ... ... the 21st Century , A Virtual Workshop Presented by WCG FDAnews and Cerulean ... 4:30 pm EDT, https://wcg.swoogo.com/modern-sop-and-quality-systems , Are one’s SOPs written for the ...
(Date:3/30/2021)... ... March 29, 2021 , ... According to data released ... reproductive age (13-44) in need of publicly funded contraception live in counties impacted by ... Colorado’s 64 counties have lost some of their Title X resources. , The ...
(Date:3/30/2021)... ... March 29, 2021 , ... Health Literacy Innovations (HLI), a ... confusion due to low health literacy today announces a new partnership with the ... work with ACAP’s member Safety Net Health Plans, those that provide comprehensive health ...
(Date:3/30/2021)... ... ... Dr. Colin Campbell is proud to announce the 1 year anniversary in their new state ... internal medicine and is a primary care specialist who has been practicing for 23 years. ... keep South Jersey healthy one patient at a time. , “Over the past year, Dr. ...
(Date:3/30/2021)... ... March 30, 2021 , ... The COVID-19 ... and survivors; their families; and their caregivers. Crossroads4Hope is addressing the needs of ... emotional support system, MyGo2Support, which meets needs of people impacted by cancer, no ...
Breaking Medicine News(10 mins):